← Cabaletta Bio, Inc. (CABA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Cabaletta Bio, Inc. (CABA)
Biological Products, (No Diagnostic Substances) · market cap $392M · as of 2026-07-07
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cabaletta Bio (CABA) is a clinical-stage autoimmune cell therapy company with a market cap of ~$520M and ~$116.6M in cash, implying roughly 8 months of runway. Its lead program, CABA-201, is advancing into Phase 3 for Idiopathic Inflammatory Myopathy (IIM) and is in Phase 2 for Generalized Myasthenia Gravis (gMG), while a separate CAART asset (DSG3-CAART) is in Phase 2 for Pemphigus Vulgaris.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CABA-201 | Phase 3 | Generalized Myasthenia Gravis (gMG) |
| DSG3-CAART | Phase 2 | Pemphigus Vulgaris |
| CABA-201 following preconditioning with fludarabine and cyclophosphamide | Phase 3 | Idiopathic Inflammatory Myopathy |
Price & technical context
3-month
-37.9%
6-month
-36.8%
12-month
-19.0%
52-wk range
$1.87–$4.15
vs 50-day MA
-32.2%
vs 200-day MA
-35.8%
Realized vol
94.6%
Max drawdown
-78.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CABA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.